Clinical Trial

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-04-07; most recent amendment 2026-03-24.
Trial Details
NCT Number NCT06925724
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Summit Therapeutics
Conditions Endometrial Cancer, Cervical Cancer
Enrollment 50 participants
Start Date 2025-04-04
Primary Completion 2027-04 (estimated)
Study Completion 2027-04-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-25